Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoline SCHEMBL28250429 | 0.90 | KMT2A (0.51) | KMT2AMEN1PDE10ARAB9AALDH1A1 | |
| SCHEMBL28505934 | 0.83 | KMT2A (0.50) | KMT2AMEN1ALDH1A1CRHBPCRHR2 | |
| SCHEMBL28241457 | 0.78 | MEN1 (0.47) | KMT2AMEN1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL28242021 | 0.78 | L3MBTL1 (0.52) | KMT2AMEN1ALDH1A1TDP1KDM4E | |
| SCHEMBL9120430 | 0.77 | RAB9A (0.55) | KMT2AMEN1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL1682777 | 0.77 | RAB9A (0.55) | KMT2AMEN1PDE10ARAB9AALDH1A1 | |
| SCHEMBL11414775 | 0.77 | MEN1 (0.54) | KMT2AMEN1RAB9AALDH1A1TDP1 | |
| Acridine SCHEMBL27545385 | 0.77 | RAB9A (0.63) | KMT2AMEN1PDE10ARAB9AALDH1A1 | |
| SCHEMBL11108095 | 0.76 | RAB9A (0.54) | KMT2AMEN1PDE10ARAB9AALDH1A1 | |
| SCHEMBL2011678 | 0.76 | RAB9A (0.54) | KMT2AMEN1RAB9AALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108558751-B | Synthesis process of 3-nitroquinoline derivative | 武汉工程大学 | 2021-01-05 | — | — | CN | disclosed |
| CN-108558750-B | Process for synthesizing 3-nitroquinoline derivative by solvent-free method | 武汉工程大学 | 2021-01-05 | — | — | CN | disclosed |
| CN-108558878-B | Synthesis process of quinoline and derivatives thereof | 武汉工程大学 | 2020-10-23 | — | — | CN | disclosed |
| CN-108558750-A | The technique that solventless method synthesizes 3- nitroquinoline derivatives | 武汉工程大学 | 2018-09-21 | — | — | CN | disclosed |
| CN-108558878-A | A kind of synthesis technology of quindoline and its derivative | 武汉工程大学 | 2018-09-21 | — | — | CN | disclosed |
| CN-108558751-A | The synthesis technology of 3- nitroquinoline derivatives | 武汉工程大学 | 2018-09-21 | — | — | CN | disclosed |
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | KMT2A 2974/4885MEN1 1164/4885PDE10A 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.